Cardiomyopathy

(redirected from Arrhythmogenic right ventricular cardiomyopathy)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Wikipedia.

cardiomyopathy

[¦kärd·ē·ō‚mī′äp·ə·thē]
(medicine)

Cardiomyopathy

 

(myocardosis), a term often applied to a broad group of heart diseases; specifically, noninflammatory lesions of the heart muscle (myocardium) resulting from a disturbance in myocardial metabolism. Among the causes of cardiomyopathy are nutritional disorders (alimentary dystrophy and avitaminosis, for example); protein metabolism disorders in hepatic or renal insufficiency and podagra; disturbances of carbohydrate metabolism (diabetes mellitus) and electrolyte metabolism; and endocrine disorders such as those associated with thyrotoxicosis and with hypoxia in impairment of coronary circulation, anemia, and mountain sickness. Myocardosis may also be caused by overstraining the myocardium and by exogenous poisons, such as carbon monoxide and alcohol.

In many cases the patient has no specific symptoms in the early stages; however, there may be shortness of breath and disagreeable sensations in the heart. Cardiomyopathy is manifested by dull, distant heart sounds, electrocardiographic changes, systolic murmur, extrasystole, and, more rarely, other types of arrhythmia. Severe cardiomyopathy weakens the heart contractions and may cause cardiac insufficiency. The changes associated with cardiomyopathy are usually reversible and disappear with the elimination of the underlying disease.

The cure includes treatment of the underlying disease and administration of agents that improve metabolic processes in the myocardium.

REFERENCE

Kedrov, A. A. Bolezni myshtsy serdtsa. Leningrad, 1963.

N. R. PALEEV

References in periodicals archive ?
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is characterized by progressive fatty or fibrofatty infiltration of the right ventricular myocardium, which constitutes a substrate for electrical instability and a focus of ventricular arrhythmias (1).
Cardiomyopathies are progressive diseases that affect the heart muscle including Hypertrophic Cardiomyopathy (HCM), Dilated Cardiomyopathy (DCM), Conduction Disease associated with DCM (CD-DCM), and Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC).
The FAMILION tests detect genetic mutations that can cause cardiac channelopathies or cardiomyopathies such as Long QT Syndrome (LQTS), Brugada Syndrome (BrS), Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), Hypertrophic Cardiomyopathy (HCM), and Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) in individuals and their families.
The FAMILION family of tests detect genetic mutations that can cause cardiac channelopathies or cardiomyopathies such as Long QT Syndrome (LQTS), Brugada Syndrome (BrS), Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), Hypertrophic Cardiomyopathy (HCM), and Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) in individuals and their families.
NASDAQ: CLDA), today announced the launch of its new genetic test for Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC), an inherited and often fatal heart condition, at the 2008 American Heart Association meeting.
Another study shows early promising results in a rare congenital disease, arrhythmogenic right ventricular cardiomyopathy.

Full browser ?